HomeQuestion

What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital?

1 Answers

Mednet Member

Medical Oncology · University Hospitals

We treat resectable pancreatic patients with neoadjuvant therapy regardless. In a fit patient, we will recommend starting with FOLFIRINOX chemotherapy. Restaging scans should be fine every 2 months. We could consider therapy for 4-6 months.

What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital? | Mednet